About Sysmex
With our business centered on the field of in vitro diagnostics, Sysmex provides instruments,
ABOUT SYSMEX reagents, and software to medical institutions and other customers worldwide.
We have created a structure for consistent research and development, production, sales, service and support in response to the diversified needs of our customers with various issues. In addition to producing high-quality instruments, reagents, and software for in vitro diagnostics, this structure allows us to offer high value-added products and services with regard to system products, online support, and advanced scientific information, which have been highly evaluated by our customers worldwide.
Sysmex's Main Business Domains (In Vitro Diagnostics)
Prevention | |||
In Vitro Diagnostics | |||
■ Hematology* | ||
Examination | Testing that measures and analyzes the number, type, and size of red, | |
white and other blood cells | ||
(Anemia, leukemia, thrombocytopenia, etc.) | ||
■ Hemostasis | ||
TestingLaboratoryClinical | Testing that measures the ability of blood to clot at wound sites and dissolve clots | |
andTreatmentDiagnosis, | (Hemophilia, myocardial infarction, cerebra linfarction, etc.) | |
■ Clinical chemistry* | ||
■ Urinalysis* | ||
Testing to determine the presence of sugar, proteins or blood in the urine | ||
(Kidney stones, kidney disease, diabetes, etc.) | ||
■ Immunochemistry | ||
Testing for the quantities and status of viruses, hormones and proteins | ||
(Infectious diseases (hepatitis B and C), thyroid disease, various cancers, | ||
Monitoring | myocardial infarction, hepatitis, atopic dermatitis, etc.) | |
Testing to determine the state of metabolism-related organs by studying sugars, | ||
lipids, proteins and others | ||
(Diabetes, arteriosclerosis, liver dysfunction, kidney dysfunction, etc.) | ||
■ Gene testing | ||
Through the detection and analysis of cancer genes, this testing contributes to | ||
Recovery | decisions on treatment protocols and drug administration. | |
(Breast cancer, lung cancer, colorectal cancer, etc.) | ||
* Diagnostics used for medical checkups as well | ||
Company Profile
■ Name : SYSMEX CORPORATION
■ Established : February 20, 1968
■ Paid-in Capital : ¥14,112.0 million (As of March 31, 2022)
■ Listings : Tokyo Stock Exchange, Prime Market (Ticker Code: 6869)
■ Directors : Chairman and CEO Hisashi Ietsugu
■ Head Office : 1-5-1Wakinohama-kaigandori,Chuo-ku, Kobe, Hyogo 651-0073, Japan
■Lines of Businesses : Development, manufacture, sales and export/import of diagnostic instruments, reagents and related software
■Main Customers : National and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc.
■ Export Destinations : More than 190 countries and regions
Financial Performance | ||||||
■ Net Sales | ■ Net Sales by Destination | ■ Sales by Business | ||||
¥363.7billion | 363.7 (¥ billion) | Others 4.6% | Medical robotics | |||
Net sales | ||||||
(Up 19.2% year on year) | Asia Pacific | Japan | Life science | business 0.4% | ||
Euro | 130.6 (¥) | 8.1% | 15.3% | 4.9% | Hematology | |
Clinical | ||||||
112.4 (¥) | 57.8% | |||||
chemistry | ||||||
US dollar | China | 0.8% | ||||
25.7% | FY2021 | Immuno- | FY2021 | |||
Yuan | ||||||
17.5 (¥) | chemistry | |||||
2012 2013 2014 2015 2016 2017 | 2018 2019 2020 | 2021 (FY) | EMEA* | Americas | 5.6% | |
Japanese GAAP | IFRS | Hemostasis | ||||
Reagent sales grew substantially, thanks to a recovery | 27.9% | 23.0% | ||||
17.1% | FCM 0.6% | |||||
in testing demand. Net sales also rose significantly, | ||||||
owing to an expansion of our direct sales area, an | * EMEA: Europe, the Middle East, and Africa | Urinalysis 8.2% | ||||
increase in the installed instrument base and a boost | ||||||
in demand for testing related to COVID-19. |
Non-Financial Performance | Japan | Americas | ||||
3,888 | 12 | 1,341 | 10 |
9,812 | 77 | |||||
Employees | Companies | |||||
(Group total) | (Group total) | |||||
China | ||||||
779 | 4 | |||||
Asia Pacific | ||||||
EMEA | 984 | 12 | ||||
2,820 | 39 |
Sysmex Sustainability Data Book 2022 2
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sysmex Corporation published this content on 24 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2022 08:03:05 UTC.